缩宫素(Oxytocin) - 药物靶点：OXTR_在研适应症：宫缩乏力，子宫出血，流产_专利_临床

概要

基本信息

简介催产素是一种以商品名OXYTOCIN®销售的OXTR激动剂，是一种因其在妇产科领域的临床疗效而受到称赞的药物。催产素由诺华公司制造，诺华是一家在药物创新方面享有盛誉的制药公司，它于1980年首次在美国获得批准。该药物主要用于产前和产后护理，因为它已被证明可以有效诱导或加强子宫收缩。它的重组激素性质使其成为全球妇产科医生的首选药物，他们为需要产前和产后护理的女性寻求可靠和值得信赖的选择。此外，已发现催产素是孕妇常用的处方药，可帮助她们分娩和分娩或控制产后出血。

药物类型

合成多肽

别名

Oxytocin (JP17/USP/INN)、Oxytocin Nasal Spray、催产素

+ [14]

靶点

OXTR

作用机制

OXTR激动剂(催产素受体激动剂)

治疗领域

泌尿生殖系统疾病其他疾病神经系统疾病+ [2]

在研适应症

宫缩乏力子宫出血流产+ [10]

非在研适应症

萎缩性阴道炎萎缩注意缺陷障碍伴多动+ [6]

原研机构

Par Sterile Products LLC

在研机构

Tonix Pharmaceuticals Holding Corp.Viatris Pty Ltd.Tonix Pharmaceuticals, Inc.

+ [2]

非在研机构

Optinose AS

GSK PlcThe General Hospital Corp.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1980-11-19),

流产出血催产+ [1]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、罕见儿科疾病 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构

分子式C43H66N12O12S2

InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N

CAS号50-56-6

序列信息

Sequence Code 124252

来源: *****

关联

829

项与缩宫素相关的临床试验

ACTRN12624001282572 / Not yet recruiting临床4期IIT

Comparative effectiveness between continuous and pulsatile (intermittent) oxytocin for induction of labour on the duration of labour in nulliparous women: A pilot study.

开始日期2025-01-01

申办/合作机构

Northern Health Authority

NCT04433741 / Withdrawn临床2期IIT

Apply the Pharmacodynamic Model of Peripheral Oxytocin Action to a Multimodal Stimulus That Increases (Heat) or Decreases (Vibration) Pain Perception

This is a study of participants that will receive an intravenous (IV) infusion of oxytocin (naturally occurring hormone that is made in the brain).
In this study healthy volunteers are recruited. Each study participant will have an IV catheter placed. After placement of the IV catheter oxytocin will be given by IV infusion of oxytocin or placebo (inactive solution). The investigators will perform some tests to evaluate how oxytocin changes perceptions on the skin. The investigators will study a painful perception by placing a probe on the skin and heating it to 116.6 degrees Fahrenheit for 30 seconds and a vibratory stimulus will be applied to the forearm with vibration begun at a 1 kHz frequency and decreased at a rate of 25 Hz/sec until the subject first perceives the vibration. Each study participant will score any pain that is experienced on a 0 to 10 scale and will report when the vibration is detected. Each participant will receive oxytocin and placebo in a random order and will be blinded to group they are receiving.

开始日期2025-01-01

申办/合作机构

Wake Forest School of Medicine

NCT04435704 / Withdrawn临床2期IIT

Validate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects

The goal of this study is to validate the pharmacodynamic model for pain relief from oxytocin at a peripheral site by intravenous infusion targeted at different levels of the drug.
In this study healthy volunteers and people with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Each study participant will have an intravenous(IV) catheter placed. After placement of the IV catheter oxytocin will be given by IV infusion in varying amounts. The study team will perform some tests to evaluate how oxytocin changes perceptions on the skin. The study team will study a painful perception by placing a probe on the skin and heating it to 113 degrees Fahrenheit for 5 minutes. Each study participant will score any pain that is experienced on a 0 to 10 scale.

开始日期2025-01-01

申办/合作机构

Wake Forest School of Medicine

100 项与缩宫素相关的临床结果

登录后查看更多信息

100 项与缩宫素相关的转化医学

登录后查看更多信息

100 项与缩宫素相关的专利（医药）

登录后查看更多信息

16,978

项与缩宫素相关的文献（医药）

2025-02-01·INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA

Anaesthetic considerations for impacted fetal head at caesarean delivery: a focused review

Review

作者: Charles, E. ; Herincs, M ; Desai, N ; Desai, N. ; Ragbourne, S.C. ; Ragbourne, S C ; Charles, E ; Herincs, M.

BACKGROUND:

Impacted fetal head occurs when the fetal head is deeply engaged within the maternal pelvis and difficult to deliver during caesarean delivery. In order to deliver the fetal head, additional surgical manoeuvres and/or pharmacological tocolysis are needed. The aim of this focused review is to outline the incidence, risk factors, management and complications of this obstetric emergency from the perspective of the anaesthetist.

METHODS:

Databases were searched for free text headings and subject headings associated with different permutations of terms related to impacted fetal head and caesarean delivery.

RESULTS:

Impacted fetal head has been estimated to occur in 1.5 % of elective caesarean deliveries and 2.9-18.4% of all emergency caesarean deliveries at any cervical dilatation. Risk factors include advanced cervical dilatation, labour augmentation with oxytocin, prolonged second stage of labour, fetal malposition and junior grade of operating obstetrician. If impacted fetal head occurs, the anaesthetist in conjunction with the multidisciplinary team should consider decreasing the height of the operating table, providing a step for the obstetrician to stand on, placing the patient in the head down position, providing pharmacological tocolysis with glyceryl trinitrate (or nitroglycerin), beta-2 adrenoreceptor agonists or volatile anaesthetic agents, and managing complications such as postpartum haemorrhage.

CONCLUSION:

Impacted fetal head is an obstetric emergency that the anaesthetist should be familiar with and has a vital role in managing. We propose an algorithm for management that may serve as a clinical decision aid.

Article

2025-01-01·PSYCHONEUROENDOCRINOLOGY

Could intranasal oxytocin enhance the effects of psychotherapy in individuals with mental disorders? A systematic review and meta-analysis

Article

作者: Vega, Daniel ; Soler, Joaquim ; Schmidt, Carlos ; Pérez-Arqueros, Valeska ; Pascual, Juan C ; Pascual, Juan C.

Interest in the therapeutic potential of oxytocin for the treatment of mental health disorders, especially those involving social dysfunction, has increased considerably in recent years. To date, most studies have only evaluated oxytocin as monotherapy, with highly inconsistent results. A new line of research is exploring the effects of combining oxytocin with psychotherapy. The aim of the present review was to evaluate the therapeutic effects of intranasal oxytocin combined with psychotherapy in individuals with psychiatric disorders. Only randomized clinical trial design was eligible for inclusion. A search of relevant databases yielded 2480 articles published through April 30, 2024. Of these, 13 trials (518 participants) were included in this review and 4 of them in a meta-analysis. The trials evaluated a range of different psychotherapeutic interventions, oxytocin doses, and mental disorders. Overall, the trials suggested that combined treatment reduced negative mental representations, decreased stress, and increased therapeutic alliance. Meta-analysis showed that combined treatment significantly reduced depressive symptoms (d= -1.58, 95 % CI: -3.15 to -0.01). However, the treatment with oxytocin had no significant effects on psychiatric symptoms (d= 0.00, 95 % CI: -0.56-0.57) or social functioning (d = 0.21, 95 % CI: -0.07-0.49). Limitations included the heterogeneity and limited sample sizes of the trials. The findings suggest that the combination of intranasal oxytocin and psychotherapy may be an effective therapeutic approach to reduce depressive symptoms in individuals with mental disorders and may improve retention and therapeutic alliance.

306

项与缩宫素相关的新闻（医药）

2024-10-29

·GlobeNewswire-Health Care

Tonix Pharmaceuticals to Present at BIO-Europe® 2024

CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET. To schedule a meeting with the Company’s management at the conference, please submit a meeting request through the partneringOne system or contact brandon.weiner@westwicke.com. Tonix Pharmaceuticals Holding Corp.*Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, and its priority is to progress TNX-102 SL, a product candidate for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor ContactJessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182 Peter VozzoICR Westwickepeter.vozzo@westwicke.com (443) 213-0505 Media ContactRay JordanPutnam Insightsray@putnaminsights.com(949) 245-5432

快速通道临床3期临床2期疫苗突破性疗法

2024-10-24

·GlobeNewswire-Health Care

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024

CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix Pharmaceuticals, will deliver an oral presentation at the World Vaccine Congress Europe, which will be held in Barcelona, Spain, October 28-31, 2024. A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine Congress Europe website here. Presentation Details Presenter:Zeil Rosenberg, M.D., M.P.H.Title:A Novel, Single-dose, Live, Attenuated, Minimally Replicating Mpox VaccineLocation:Fira de Barcelona - Montjuïc - Hall 2Date:Wednesday, October 30, 2024Time:2:10 p.m. GMT Tonix Pharmaceuticals Holding Corp.* Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, and its priority is to progress TNX-102 SL, a product candidate for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@westwicke.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432

疫苗快速通道临床2期突破性疗法临床3期

2024-10-23

·药渡Daily

跨界并购加速，制药业或将不再纯粹

区别于普通制造业，制药业是一个门槛很高的行业，不论从技术标准、研发难度，还是政策监管等层面，制药业面临的难度都更大，毕竟关乎民生关乎生命健康，不容儿戏。因此也造成了制药业整体较为纯粹的局面，多数药企专注研发、生产和销售药品，较少跨界从事其他行业。但随着政策开始鼓励跨界并购，在当前行业整体低迷的局势下，药企或将被并购，被重组，以至于不再那么纯粹。当然，这是时代进步和资本发展的必经之路，但同时也意味着制药业的动荡将更加剧烈。瞄准GLP-1 又一桩并购案引起大量关注。 10月21日晚，四川和谐双马股份有限公司（“四川双马”）发布公告称，拟使用自有及自筹资金以总计15.96亿元购买深圳市健元医药科技有限公司（“深圳健元”）92.1745%的股权。交易实施完毕后，深圳健元将成为四川双马合并报表范围内的控股子公司。被收购后深圳健元的股权结构来源：公告这起并购交易的瞩目点在于跨界。被并购方深圳健元是一家多肽产品的自主研发、生产、销售与定制研发生产相结合的生物医药企业，成立于2009年，建有一个研发中心和两大生产基地，化学合成多肽总产能现已达数吨级规模，位居行业前列。深圳健元的营收以多肽类原料药业务为主，多肽类原料药产品主要包括司美格鲁肽、替尔泊肽、利拉鲁肽、地加瑞克和缩宫素等20多个品种，其中司美格鲁肽、替尔泊肽等5个品种已完成美国FDA DMF备案；CDMO业务包括项目制的受托研发、受托生产以及定制肽的销售；美容肽业务为用于化妆品原料的生产制造，主要产品包括铜肽、乙酰基六肽、芋螺肽、美容肽复配等一系列产品，用于抗衰老和抗皱，主要供应全球头部化妆品企业。四川双马成立于1998年，曾经的主业为水泥建材的生产，受累于房地产行业下行，水泥行业整体走弱，四川双马的主要利润来源已变成私募股权投资业务，其私募股权投资基金管理公司西藏锦合目前在管基金规模近280亿元。 2023年报显示，四川双马水泥业务收入为5.76亿元、私募股权投资基金管理业务收入4.66亿元，骨料业务收入为1.78亿元；2024年上半年，私募股权投资基金管理主营业务收入2.21亿元，已反超水泥业务的1.93亿元。 2024年上半年四川双马营收组成来源：半年报作为一家私募股权投资基金管理公司，四川双马的投资敏锐性毋庸置疑，其瞄准的或是当前多肽原料药供不应求的市场空窗期。深圳健元的生产基地湖北健翔主要生产GLP-1类多肽原料药以及其他多肽原料品种，并生产CDMO业务中部分项目的多肽原料产品。该生产基地占地300亩，总建筑面积约54000平米，建有4个多肽生产车间，已通过国家药监局官方GMP符合性检查，多肽原料年产能已达数吨级规模，其中GLP-1类产品最大单批产量国内领先。在一场以GLP-1为核心的市场争夺战正式打响之前，拥有的产能越大，未来的市场定价话语权就更大。根据弗若斯特沙利文数据，2016-2021年，中国多肽类药物市场规模持续增长，从416.6亿元增长至621.2亿元，预计到将2030年达2056.5亿元；同期，中国多肽原料药市场规模从34.1亿元增至76.2亿元，预计2025年将达到237.5亿元，2030年将达到652.5亿元。巨大的市场诱惑，使得四川双马不惜大幅溢价也要拿下深圳健元。 2023年和2024年上半年，深圳健元营收分别为3.2亿元、2.16亿元，净利润分别为1.41亿、6232.88万元，截止2024年上半年的净资产为6.09亿元。四川双马以15.96亿元购买92.1745%的股权，对应深圳健元的整体估值约为17.31亿元。在GLP-1热点的加持下，四川双马在资本市场上可能将走出双成药业一般令人瞠目结舌的走势。神话故事双成药业的并购案已成近期资本市场的神话故事，23个交易日21个涨停板，高达6倍的涨幅，即使放在期待中的牛市也让人直呼不可能。但这就是事实。十分凑巧，在神话故事开始以前，双成药业的主营业务也为多肽药物，已成功开发了多个化学合成多肽药物和20个其他各种治疗类药物。其中多肽类药物主要有注射用胸腺法新（“基泰”）、注射用生长抑素、注射用比伐芦定、依替巴肽注射液等。其他产品还包括阿托伐他汀钙片、盐酸二甲双胍片、维生素C注射液、氨氯地平片等。从这些产品中我们可以看出，没有创新药的双成药业在集采时代应该不太好过。的确，从2016年起，双成药业的扣非净利润均为亏损。2024年上半年，其总营收9489.26万元，同比下降31.74%；扣非净利润-1775.95万元。双成药业近年财务数据来源：公告而神话故事源起的并购案，也是一起跨界并购案。并购对象宁波奥拉半导体股份有限公司（“奥拉股份”）是一家以自主研发、销售服务为主体的高性能模拟电路芯片设计公司。目前，奥拉股份成为中兴通讯、锐捷网络、华勤技术、新华三、中国长城等国内10多家大型通信基础设施企业的去抖时钟芯片产品供应商。根据Market Data Forecast数据显示，2021年奥拉股份在全球去抖时钟芯片市场份额为10.19%，在国内排名第一。此前，奥拉股份曾一度冲击科创板，IPO前的最后一轮股份转让中，其估值达到了100亿元。并购完成后，双成药业将一跃成为当前最具前景价值的半导体公司。双成药业表示，交易完成后，公司将发展重心转移到半导体行业中的模拟芯片及数模混合芯片的研发、设计和销售业务，并在未来择机剥离医药类相关资产。随着“并购六条”的发布，未来我们将看到越来越多的并购案、跨界并购案，获将出现很多不同行业混合经营的公司，以高门槛为主要特征的制药业或许将不再纯粹。行业动荡加剧 9月24日，中国证监会发布了《关于深化上市公司并购重组市场改革的意见》（简称“并购六条”），一系列政策举措为并购重组市场带来了前所未有的新机遇，特别是跨界并购与未盈利资产收购方面，更是引发了市场的广泛关注和热议。主要内容包括支持上市公司向新质生产力方向转型升级、鼓励上市公司加强产业整合、提高监管包容度、提升重组市场交易效率、提升中介机构服务水平、依法加强监管六大方面内容，旨在进一步激发并购重组市场活力，支持经济转型升级和高质量发展。在制药行业，十数年前行业的并购重组十分频繁，许多知名的药企正是在那个时期通过并购成长起来。但同样也有很多药企，因频繁并购造成商誉过高，最终陨落。不过自进入集采时代以来，多数药企为应对集采的冲击，或缩减产能，或积极转型，并购重组较少发生。一些未能成功转型的药企光维持生计就已十分吃力，也再没有心力并购重组。而且过往的并购重组案中，行业内的兼并占多数，跨界并购案极少。从全球范围内看，药企发展的最终形态MNC（跨过制药巨头），主要战略便是在各地并购有发展潜力的Biotech。 2023年，全球范围内的制药行业超过10亿美元的并购有26笔，总金额约1500亿美元，出现了辉瑞430亿美元收购Seagen这样的巨额并购案。2024年以来，超10亿美元的并购案已超20笔。从企业来看，诺华、默沙东、强生、诺和诺德、阿斯利康、GSK正加速扩张。国内方面，也出现了多起备受瞩目的并购案。今年7月，景峰医药开始出现异动，数十个涨停板让人愕然。主要原因是石药集团入主了景峰医药，使得这家徘徊在退市边缘的药企重新活了过来。根据此前石药集团将创新资产装入新诺威的事件推测，石药集团很有可能将旗下纳米制剂、细胞疗法和siRNA等众多创新资产转入景峰医药，实现“曲线回A”。嘉和生物“反向并购”亿腾医药也在近期一段时间被市场津津乐道。根据嘉和生物公告显示，亿腾医药将以合并方式收购嘉和生物，该交易以换股形式进行，在合并后的新公司中原亿腾医药股东占比77.43%，原嘉和生物股东占比22.57%，亿腾医药实际控制人倪昕将成为合并公司的控股股东，占有的股份达37.60%。这一交易完成后，嘉和生物将更名为“亿腾嘉和医药集团有限公司”。这两起并购案，连同上述双成药业的跨界并购案，都有“借壳上市”资本运作的印记，主要原因或许是IPO收紧的影响。结语随着越来越多的国内药企逐渐走出集采阴霾，创新转型也步入正轨，在“并购六条”的积极推动下，或许制药行业的并购案将重新频繁起来。依照行业规律，我们或将看到，一些拥有较为优质资产但研发资金即将燃烧殆尽的Biotech将被Bigpharma吃下，一些中型药企将各取所需并为一处做大做强，一些Bigpharma将进一步进化为MNC。沉寂许久的制药业，要再次活跃起来了。后续发展如何，药渡还将持续关注。参考资料各大公司公告、官网、年报等《上半年协议收购超1800起医药行业并购现“模范大股东”》，有连云，2024-07-15 《并购新篇章：证监会“并购六条”政策全解读》，新浪财经，2024-10-10 《四川双马超两倍溢价收购减肥药原料商，标的值不值这个价？》，界面新闻，2024-10-22 《奥拉股份借双成药业曲线上市，10个涨停后，未来能否双赢？》，红刊财经，2024-9-26

并购

100 项与缩宫素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00089	缩宫素	H01BB02	DB00107

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
宫缩乏力	澳大利亚	Viatris Pty Ltd.	1991-08-21
子宫出血	日本	ASKA Pharmaceutical Co., Ltd.	1984-07-12
流产	美国	Endo Operations Ltd.	1980-11-19
出血	美国	Endo Operations Ltd.	1980-11-19
催产	美国	Endo Operations Ltd.	1980-11-19
产后出血	美国	Endo Operations Ltd.	1980-11-19
人工流产	-	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
社交恐怖症	临床2期	美国	Tonix Pharmaceuticals, Inc.	2023-07-17
儿童肥胖	临床2期	美国	Tonix Pharmaceuticals, Inc.	2023-07-10
肥胖	临床2期	美国	The General Hospital Corp.	2017-07-01
躯体变形障碍	临床2期	美国	The General Hospital Corp.	2014-12-01
短指D型	临床2期	美国	The General Hospital Corp.	2014-12-01
强迫症	临床2期	美国	The General Hospital Corp.	2014-12-01
萎缩	临床2期	瑞典	Peptonic Medical AB	2014-10-01
自闭症谱系障碍	临床2期	美国	The General Hospital Corp.	2014-04-01
丛集性头痛	临床2期	澳大利亚	Trigemina, Inc.	2013-05-01
丛集性头痛	临床2期	智利	Trigemina, Inc.	2013-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04946006 (Pubmed \| Can J Anaesth)	N/A	维持	40	Oxytocin maintenance infusion 4.5 IU/hr	壓繭艱觸窪艱鑰鹽顧積(鹹鬱襯築襯憲積壓獵網) = 餘膚鑰壓蓋獵鏇願鏇膚築鹹積醖艱網網餘獵範 (窪蓋壓網鹹憲構獵衊淵 ) 更多	积极	2024-09-19
NCT05672667 (CTgov)	临床1期	-	25	intravenous oxytocin	顧繭製鬱簾齋築網遞鹽(窪襯鬱壓鹹簾鹹艱膚壓) = 餘衊糧製簾築觸廠觸淵糧窪齋鬱選積積鏇鬱願 (齋壓鹹膚製膚齋構鏇壓, 夢築構積鹽網繭蓋顧廠 ~ 醖壓範築構鑰範醖餘齋) 更多	-	2024-08-06
NCT03593473 (CTgov)	临床2期	产后抑郁症 \| 心理压力 \| 焦虑症	109	Intranasal Oxytocin (Intranasal Oxytocin)	鏇製獵觸壓獵範製鑰鏇(製鹹鹽築獵網鏇積壓壓) = 鹹遞顧醖觸艱網鏇鹹繭憲餘憲壓鹹鹹遞積遞獵 (窪鬱網蓋蓋鬱網壓鹹醖, 願鹹餘鹹網廠餘積艱鬱 ~ 醖築艱顧醖獵獵艱壓構) 更多	-	2024-05-24
				Placebo (Placebo)	鏇製獵觸壓獵範製鑰鏇(製鹹鹽築獵網鏇積壓壓) = 鑰蓋壓選壓鹹鏇憲築夢憲餘憲壓鹹鹹遞積遞獵 (窪鬱網蓋蓋鬱網壓鹹醖, 選觸壓鏇積鑰艱襯繭膚 ~ 製鹽選憲遞淵蓋觸鑰窪) 更多
ChiCTR2300067953 (Pubmed \| Arch Gynecol Obstet)	N/A	-	360	Intravenous infusion of oxytocin	醖築鏇製範鬱淵範膚齋(顧獵簾壓觸遞衊淵鑰鹹) = 範鏇觸糧憲醖鹹蓋鏇襯醖糧齋鬱鬱簾廠齋鏇鹹 (簾繭鹽餘餘膚構膚簾顧, 21.7)	不佳	2024-05-16
				Intramyometrial injection of oxytocin	醖築鏇製範鬱淵範膚齋(顧獵簾壓觸遞衊淵鑰鹹) = 選鬱壓窪鏇願顧餘選艱醖糧齋鬱鬱簾廠齋鏇鹹 (簾繭鹽餘餘膚構膚簾顧, 24.3)
NCT04028765 (POM PROM, CTgov)	临床4期	胎膜早破	108	Misoprostol (Oral Misoprostol)	鏇憲淵製蓋願窪鏇齋壓(廠齋觸鑰簾願繭糧範積) = 衊襯艱蓋積艱觸獵範壓齋鑰鏇築遞壓廠願醖糧 (遞獵醖廠夢鏇醖鹽衊獵, 衊窪憲鑰選醖繭鏇淵構 ~ 積壓餘簾餘糧簾選遞憲) 更多	-	2024-04-30
				Oxytocin (Oxytocin)	鏇憲淵製蓋願窪鏇齋壓(廠齋觸鑰簾願繭糧範積) = 鏇繭鏇繭網鬱膚製選繭齋鑰鏇築遞壓廠願醖糧 (遞獵醖廠夢鏇醖鹽衊獵, 網觸夢鑰製夢觸鏇獵膚 ~ 顧淵鑰齋廠製艱壓構獵) 更多
NCT03043053 (Pubmed)	临床2期	肥胖	-	Intranasal Oxytocin (24 IU)	網鏇簾廠觸構淵鏇鹹艱(遞窪遞壓鹹廠夢壓願糧) = 壓鑰鏇鹹鹽窪壓鬱衊築壓積窪襯憲顧簾願齋夢 (繭齋遞膚艱網獵醖獵願, -152.0) 更多	不佳	2024-04-23
				Placebo	網鏇簾廠觸構淵鏇鹹艱(遞窪遞壓鹹廠夢壓願糧) = 鹹遞窪繭窪醖繭膚製膚壓積窪襯憲顧簾願齋夢 (繭齋遞膚艱網獵醖獵願, -302.3 ~ -1.7) 更多
NCT02918864 (ION-ASD, CTgov)	临床2期	自闭症谱系障碍	40	Social Cognitive Skills Training+Oxytocin (ION-ASD)	窪鏇積築壓築夢範襯網(築衊網蓋願衊選觸鏇窪) = 製艱簾齋廠憲襯齋積鏇夢鑰網憲膚鹹襯糧製窪 (鏇鏇繭鑰窪蓋鏇糧鑰襯, 艱醖積齋顧簾鑰鹽鬱網 ~ 壓築襯齋範廠醖鑰蓋鏇) 更多	-	2024-04-05
				Facilitated Play Therapy (Facilitated Play)	窪鏇積築壓築夢範襯網(築衊網蓋願衊選觸鏇窪) = 淵遞鏇築鑰鏇願鏇鬱夢夢鑰網憲膚鹹襯糧製窪 (鏇鏇繭鑰窪蓋鏇糧鑰襯, 膚壓壓夢簾壓壓製觸鹹 ~ 夢鬱獵廠遞餘獵積糧繭) 更多
NCT03043053 (CTgov)	临床2期	肥胖	61	oxytocin nasal spray (Oxytocin)	鏇憲願壓醖夢製鏇遞構(選鏇繭蓋構構繭襯構願) = 淵獵艱鏇遞積鬱夢淵築衊積窪廠醖鹽窪壓糧範 (醖夢齋顧製簾餘壓襯餘, 構醖遞壓憲願鏇顧繭膚 ~ 艱蓋遞網顧獵鑰簾蓋顧) 更多	-	2024-02-07
				Placebo (Placebo)	鏇憲願壓醖夢製鏇遞構(選鏇繭蓋構構繭襯構願) = 膚淵範網蓋顧觸築夢遞衊積窪廠醖鹽窪壓糧範 (醖夢齋顧製簾餘壓襯餘, 繭醖顧範積鑰糧獵糧鏇 ~ 壓遞鹽製鑰壓艱窪醖鑰) 更多
NCT02205034 (OTBB2, CTgov)	临床1/2期	普拉德-威利综合症	18	oxytocin (First Arm)	網衊壓衊艱範襯鏇網製(齋遞餘夢繭襯鹽夢構鑰) = 衊願獵獵積築廠鑰顧醖鹽膚積網顧艱糧蓋鹽遞 (簾齋鑰廠積壓窪醖範壓, 積選艱範遞廠齋醖壓顧 ~ 壓壓鏇餘獵夢鑰積膚鑰) 更多	-	2023-12-04
				oxytocin (Second Arm)	網衊壓衊艱範襯鏇網製(齋遞餘夢繭襯鹽夢構鑰) = 壓醖鏇夢鏇獵淵壓壓鹽鹽膚積網顧艱糧蓋鹽遞 (簾齋鑰廠積壓窪醖範壓, 齋顧網鹽簾築醖築窪遞 ~ 艱醖壓餘窪廠獵鑰鑰獵) 更多
NCT04017247 (Pubmed \| Am J Obstet Gynecol MFM)	N/A	-	153	Continuous oxytocin infusion	齋齋鑰鹹製構觸夢餘築(範鑰築醖繭積膚壓餘繭) = 襯構夢範衊壓鑰遞繭壓範鹹鏇鹽襯襯鑰積繭衊 (壓窪網鹽醖衊鏇鏇簾製 ) 更多	积极	2023-12-01
				Intermittent oxytocin infusion	齋齋鑰鹹製構觸夢餘築(範鑰築醖繭積膚壓餘繭) = 鬱築繭顧蓋選餘襯選遞範鹹鏇鹽襯襯鑰積繭衊 (壓窪網鹽醖衊鏇鏇簾製 ) 更多